AQAnne Marie Queenan

Anne Marie Queenan

*This is an algorithmically generated author record based on publicly available information.

Anne Marie Queenan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Karen Bush

    Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202 South, Raritan, New Jersey 08869,1 Basilea Pharmaceutica Ltd., Grenzacherstrasse 487, P.O. Box, CH-4005 Basel, Switzerland2

    4 shared publications
  • Wenchi Shang

    Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202 South, Raritan, New Jersey 08869,1 Basilea Pharmaceutica Ltd., Grenzacherstrasse 487, P.O. Box, CH-4005 Basel, Switzerland2

    2 shared publications
  • Barbara Foleno

    Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869

    1 shared publication
  • Colleen Gownley

    Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869

    1 shared publication
  • Ellyn Wira

    Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869

    1 shared publication
  • John Quinn

    Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, New Jersey,1 Loyola University Medical Center, Maywood, Illinois,2 CIDRI, John H. Stroger Hospital of Cook County, Chicago, Illinois3

    1 shared publication

Latest Publications

  • Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D

    by Anne Marie Queenan, Wenchi Shang, Malgosia Kania, Malcolm G. P. Page, Karen Bush

    The interactions of ceftobiprole with purified β-lactamases from molecular classes A, B, C, and D were determined and compared with those of benzylpenicillin, cephaloridine, cefepime, and ceftazidime. Enzymes were selected from functional groups 1, 2a, 2b, 2be, 2d, 2e, and 3 to represent β-lactamases from organisms within the antibacterial spectrum of ceftobiprole. Ceftobiprole was refractory to hydrolysis by the common staphylococcal PC1 β-lactamase, the class A TEM-1 β-lactamase, and the class C AmpC β-lactamase but was labile to hydrolysis by class B, class D, and class A extended-spectrum β-lactamases. Cefepime and ceftazidime followed similar patterns. In most cases, the hydrolytic stability of a substrate correlated with the MIC for the producing organism. Ceftobiprole and cefepime generally had lower MICs than ceftazidime for AmpC-producing organisms, particularly AmpC-overexpressingEnterobacter cloacaeorganisms. However, all three cephalosporins were hydrolyzed very slowly by AmpC cephalosporinases, suggesting that factors other than β-lactamase stability contribute to lower ceftobiprole and cefepime MICs against many members of the familyEnterobacteriaceae.


  • Top Cited Papers
    Open Access

    Carbapenemases: the Versatile β-Lactamases

    by Anne Marie Queenan, Karen Bush

    SUMMARY: Carbapenemases are β-lactamases with versatile hydrolytic capacities. They have the ability to hydrolyze penicillins, cephalosporins, monobactams, and carbapenems. Bacteria producing these β-lactamases may cause serious infections in which the carbapenemase activity renders many β-lactams ineffective. Carbapenemases are members of the molecular class A, B, and D β-lactamases. Class A and D enzymes have a serine-based hydrolytic mechanism, while class B enzymes are metallo-β-lactamases that contain zinc in the active site. The class A carbapenemase group includes members of the SME, IMI, NMC, GES, and KPC families. Of these, the KPC carbapenemases are the most prevalent, found mostly on plasmids inKlebsiella pneumoniae. The class D carbapenemases consist of OXA-type β-lactamases frequently detected inAcinetobacter baumannii. The metallo-β-lactamases belong to the IMP, VIM, SPM, GIM, and SIM families and have been detected primarily inPseudomonas aeruginosa; however, there are increasing numbers of reports worldwide of this group of β-lactamases in theEnterobacteriaceae. This review updates the characteristics, epidemiology, and detection of the carbapenemases found in pathogenic bacteria.


  • SME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing β-Lactamases

    by Anne Marie Queenan, Wenchi Shang, Paul Schreckenberger, Karen Lolans, Karen Bush, John Quinn

    Imipenem-resistant Serratia marcescens isolates were cultured from a lung transplant patient given multiple antibiotics over several months. The strains expressed SME-3, a β-lactamase of the rare SME carbapenem-hydrolyzing family. SME-3 differed from SME-1 by a single amino acid substitution of tyrosine for histidine at position 105, but the two β-lactamases displayed similar hydrolytic profiles.


  • Open Access

    Effects of Inoculum and β-Lactamase Activity in AmpC- and Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology

    by Anne Marie Queenan, Barbara Foleno, Colleen Gownley, Ellyn Wira, Karen Bush

    Escherichia coli and Klebsiella pneumoniae isolates with extended-spectrum β-lactamases (ESBLs) or AmpC cephalosporinases generally respond as predicted to NCCLS tests for ESBL production. However, inoculum size may affect MICs. The effect of inoculum level in clinical isolates expressing β-lactamases were studied at inocula within 0.5 log unit of the standard inoculum, using broth microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztreonam. Strains with TEM-1 or no β-lactamases gave consistent MIC results with inocula of 10 5 and 10 6 CFU/ml. When the bacteria were screened for ESBL production and the lower inoculum was used, several strains with ESBLs, including CTX-M-10, TEM-3, TEM-10, TEM-12, TEM-6, SHV-18, and K1, gave false-negative results for one or more antimicrobial agents (MICs below the NCCLS screening concentration for detecting suspected ESBLs). When the higher inoculum was used, MICs of at least one antimicrobial agent increased at least fourfold in strains producing TEM-3, TEM-10, TEM-28, TEM-43, SHV-5, SHV-18, and K1. All antimicrobial agents showed an inoculum effect with at least one ESBL producer. Confirmatory clavulanate effects were seen for both inocula for all ESBL-producing strains with all antimicrobial agents tested, except for the CTX-M-10-producing E. coli with ceftazidime and the SHV-18-producing K. pneumoniae with cefotaxime. In kinetic studies, cefpodoxime and cefepime were hydrolyzed by ESBLs in a manner similar to that of cefotaxime. When total β-lactamase activity and hydrolysis parameters were evaluated, however, no single factor was predictive of inoculum effects. These results indicate that the NCCLS screening and confirmation tests are generally predictive of ESBL production, but false-negative results can arise when a lower inoculum is used in testing.